National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/12892

TDMS Study 90004-06 Pathology Tables

NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21

                                                           FINAL/MICE




       Facility:  Battelle Northwest

       Chemical CAS #:  57018-52-7

       Lock Date:  12/11/00

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 8           10            6            4                                     
    Natural Death                                      3            3            2            6                                     
    Accidently Killed                                               1                         1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                39           36           41           38                                     
    Natural Death                                                                1            1                                     
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           49                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Gallbladder                                        (40)         (39)         (43)         (33)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Intestine Large, Colon                             (48)         (49)         (50)         (48)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                                1 (2%)                                             
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Intestine Large, Rectum                            (48)         (49)         (50)         (48)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                                1 (2%)                                             
   Intestine Large, Cecum                             (49)         (48)         (49)         (46)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Leiomyoma                                                                               1 (2%)                                
   Intestine Small, Duodenum                          (49)         (47)         (50)         (46)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Intestine Small, Jejunum                           (49)         (48)         (48)         (47)                                   
      Carcinoma                                                                               1 (2%)                                
   Intestine Small, Ileum                             (49)         (48)         (48)         (45)                                   
      Carcinoma                                        1 (2%)                                                                       
      Sarcoma, Metastatic, Skin                                     1 (2%)                                                          
   Liver                                              (49)         (50)         (50)         (49)                                   
      Cholangioma                                                                             1 (2%)                                
      Hemangioma                                                                              1 (2%)                                
      Hemangiosarcoma                                               2 (4%)                                                          
      Hepatoblastoma                                                                          2 (4%)                                
      Hepatocellular Carcinoma                         4 (8%)       8 (16%)      6 (12%)      8 (16%)                               
      Hepatocellular Carcinoma, Multiple                                         1 (2%)       2 (4%)                                
      Hepatocellular Adenoma                           8 (16%)      8 (16%)      7 (14%)      5 (10%)                               
      Hepatocellular Adenoma, Multiple                 6 (12%)                   3 (6%)      32 (65%)                               
      Hepatocholangiocarcinoma                                                   1 (2%)                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
      Histiocytic Sarcoma                              1 (2%)                    1 (2%)       1 (2%)                                
   Mesentery                                          (17)         (21)         (13)         (2)                                    
      Hemangiosarcoma                                  1 (6%)                                                                       
      Hepatocholangiocarcinoma, Metastatic, Liver                                1 (8%)                                             
   Pancreas                                           (49)         (50)         (50)         (48)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                                1 (2%)                                             
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Salivary Glands                                    (50)         (50)         (50)         (49)                                   
   Stomach, Forestomach                               (49)         (50)         (50)         (48)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Squamous Cell Papilloma                                                    1 (2%)       1 (2%)                                
   Stomach, Glandular                                 (49)         (48)         (50)         (48)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)         (50)         (49)                                   
      Sarcoma, Metastatic, Uncertain Primary Site                                1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (49)         (50)         (50)         (48)                                   
      Carcinoma                                        1 (2%)                                                                       
      Hepatocellular Carcinoma, Metastatic, Liver                   1 (2%)                                                          
   Adrenal Medulla                                    (47)         (49)         (50)         (48)                                   
      Pheochromocytoma Malignant                                    1 (2%)                                                          
   Islets, Pancreatic                                 (49)         (50)         (50)         (48)                                   
      Adenoma                                          1 (2%)                                                                       
   Pituitary Gland                                    (48)         (49)         (47)         (46)                                   
      Pars Distalis, Adenoma                           9 (19%)     11 (22%)     12 (26%)      8 (17%)                               
      Pars Intermedia, Adenoma                                      1 (2%)       1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Peritoneum                                                      (1)          (2)                                                 
      Hepatocholangiocarcinoma, Metastatic, Liver                                1 (50%)                                            
      Histiocytic Sarcoma                                                        1 (50%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (50)         (49)         (49)         (48)                                   
      Carcinoma                                                     1 (2%)                                                          
      Cystadenoma                                      2 (4%)       1 (2%)       3 (6%)       1 (2%)                                
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Luteoma                                          2 (4%)                    1 (2%)       1 (2%)                                
   Uterus                                             (50)         (50)         (50)         (48)                                   
      Adenoma                                          1 (2%)                                                                       
      Hemangiosarcoma                                                            2 (4%)                                             
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Leiomyoma                                                                  2 (4%)                                             
      Leiomyosarcoma                                                                          1 (2%)                                
      Polyp Stromal                                                 1 (2%)       1 (2%)                                             
      Sarcoma Stromal                                  1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (49)         (50)         (50)         (48)                                   
      Hemangiosarcoma                                               1 (2%)                                                          
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Lymph Node                                         (4)          (8)          (6)          (2)                                    
      Lumbar, Hemangiosarcoma                                                    1 (17%)                                            
   Lymph Node, Bronchial                              (45)         (34)         (44)         (42)                                   
      Histiocytic Sarcoma                              1 (2%)                                                                       
   Lymph Node, Mandibular                             (44)         (45)         (45)         (34)                                   
      Histiocytic Sarcoma                                                                     1 (3%)                                
   Lymph Node, Mesenteric                             (48)         (48)         (48)         (48)                                   
      Histiocytic Sarcoma                                                        1 (2%)       1 (2%)                                
   Lymph Node, Mediastinal                            (40)         (41)         (41)         (31)                                   
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                     1 (2%)                                                          
      Hepatocholangiocarcinoma, Metastatic, Liver                                1 (2%)                                             
      Histiocytic Sarcoma                              1 (3%)                    1 (2%)                                             
   Spleen                                             (49)         (50)         (50)         (48)                                   
      Hemangiosarcoma                                               1 (2%)                                                          
      Histiocytic Sarcoma                              1 (2%)                    1 (2%)       1 (2%)                                
   Thymus                                             (45)         (45)         (46)         (42)                                   
      Sarcoma, Metastatic, Uncertain Primary Site                                1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (50)         (50)         (49)                                   
      Subcutaneous Tissue, Hemangiosarcoma                          1 (2%)                                                          
      Subcutaneous Tissue, Mast Cell Tumor Benign                   1 (2%)                                                          
      Subcutaneous Tissue, Sarcoma                     1 (2%)       7 (14%)      1 (2%)       2 (4%)                                
      Subcutaneous Tissue, Sarcoma, Multiple                        1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (50)         (50)         (49)                                   
      Histiocytic Sarcoma                                                                     1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Larynx                                             (50)         (50)         (50)         (48)                                   
   Lung                                               (50)         (50)         (50)         (49)                                   
      Alveolar/Bronchiolar Adenoma                     2 (4%)       2 (4%)       2 (4%)                                             
      Alveolar/Bronchiolar Carcinoma                   1 (2%)       3 (6%)                    1 (2%)                                
      Alveolar/Bronchiolar Carcinoma, Multiple                                   1 (2%)                                             
      Carcinoma, Metastatic, Harderian Gland                        1 (2%)                    2 (4%)                                
      Carcinoma, Metastatic, Ovary                                  1 (2%)                                                          
      Hepatocellular Carcinoma, Metastatic, Liver      1 (2%)       4 (8%)       2 (4%)       3 (6%)                                
      Hepatocholangiocarcinoma, Metastatic, Liver                                1 (2%)                                             
      Histiocytic Sarcoma                              1 (2%)                    1 (2%)       1 (2%)                                
      Sarcoma, Metastatic, Skin                                                  1 (2%)                                             
      Sarcoma, Metastatic, Uncertain Primary Site                                1 (2%)                                             
   Nose                                               (50)         (50)         (49)         (49)                                   
      Carcinoma, Metastatic, Harderian Gland                        1 (2%)                                                          
   Pleura                                                          (1)          (1)                                                 
      Sarcoma, Metastatic, Uncertain Primary Site                                1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (50)         (50)         (50)         (48)                                   
      Carcinoma, Metastatic, Harderian Gland                        1 (2%)                    1 (2%)                                
   Harderian Gland                                    (50)         (50)         (50)         (49)                                   
      Adenoma                                          3 (6%)       4 (8%)       5 (10%)      3 (6%)                                
      Carcinoma                                                     2 (4%)                    2 (4%)                                
      Bilateral, Adenoma                                                                      1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (49)         (50)         (50)         (48)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Urinary Bladder                                    (50)         (49)         (50)         (47)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(49)                                   
      Histiocytic Sarcoma                              1 (2%)                    1 (2%)       1 (2%)                                
      Lymphoma Malignant                              13 (26%)     15 (30%)     10 (20%)      7 (14%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            37          39          36          47                                       
     Total Primary Neoplasms                           58          72          62          82                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 25          24          28          39                                       
     Total Benign Neoplasms                            34          29          38          55                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              23          30          20          22                                       
     Total Malignant Neoplasms                         24          43          24          27                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1           8           5           5                                       
     Total Metastatic Neoplasm                          1          11          14           6                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                       1                                                   
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50                                     
  Early Deaths                                                                                                                      
    Natural Death                                     11            4            4            5                                     
    Moribund Sacrifice                                 4            6            6            8                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                35           40           40           37                                     
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Gallbladder                                        (38)         (41)         (39)         (40)                                   
      Sarcoma, Metastatic, Mesentery                                             1 (3%)                                             
   Intestine Large, Cecum                             (43)         (47)         (48)         (48)                                   
      Carcinoma, Metastatic, Intestine Small,                                                                                       
          Jejunum                                      1 (2%)                                                                       
      Polyp Adenomatous                                                                       1 (2%)                                
   Intestine Small, Duodenum                          (43)         (48)         (47)         (44)                                   
      Polyp Adenomatous                                             2 (4%)       1 (2%)                                             
   Intestine Small, Jejunum                           (42)         (47)         (47)         (45)                                   
      Carcinoma                                        2 (5%)       1 (2%)       1 (2%)       1 (2%)                                
      Polyp Adenomatous                                1 (2%)                    1 (2%)       1 (2%)                                
   Intestine Small, Ileum                             (43)         (47)         (46)         (46)                                   
      Carcinoma                                                                  1 (2%)                                             
   Liver                                              (50)         (49)         (50)         (50)                                   
      Hemangiosarcoma                                  2 (4%)                    1 (2%)       1 (2%)                                
      Hepatoblastoma                                                             1 (2%)       5 (10%)                               
      Hepatocellular Carcinoma                         8 (16%)      7 (14%)     11 (22%)      9 (18%)                               
      Hepatocellular Carcinoma, Multiple               1 (2%)       1 (2%)       2 (4%)       2 (4%)                                
      Hepatocellular Adenoma                          15 (30%)     16 (33%)     14 (28%)     13 (26%)                               
      Hepatocellular Adenoma, Multiple                 3 (6%)       7 (14%)     12 (24%)     23 (46%)                               
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (2%)                                                                       
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (2%)                                                                       
      Sarcoma, Metastatic, Mesentery                                             1 (2%)                                             
   Mesentery                                          (14)         (16)         (13)         (11)                                   
      Carcinoma, Metastatic, Intestine Small,                                                                                       
          Jejunum                                      1 (7%)                                                                       
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
      Hemangiosarcoma                                               2 (13%)                                                         
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (7%)                                                                       
      Sarcoma                                                                    1 (8%)                                             
   Pancreas                                           (48)         (49)         (50)         (50)                                   
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (2%)                                                                       
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (2%)                                                                       
      Sarcoma, Metastatic, Mesentery                                             1 (2%)                                             
   Salivary Glands                                    (50)         (50)         (50)         (50)                                   
   Stomach, Forestomach                               (48)         (49)         (50)         (50)                                   
      Carcinoma, Metastatic, Intestine Small,                                                                                       
          Jejunum                                      1 (2%)                                                                       
      Mast Cell Tumor Malignant, Metastatic, Bone                                                                                   
          Marrow                                                                 1 (2%)                                             
      Epithelium, Squamous Cell Carcinoma                           1 (2%)                                                          
      Epithelium, Squamous Cell Papilloma                                        1 (2%)                                             
   Stomach, Glandular                                 (46)         (48)         (50)         (48)                                   
      Mast Cell Tumor Malignant, Metastatic, Bone                                                                                   
          Marrow                                                                 1 (2%)                                             
      Sarcoma, Metastatic, Mesentery                                             1 (2%)                                             
   Tongue                                                                                    (1)                                    
      Squamous Cell Papilloma                                                                 1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)         (50)         (50)                                   
      Carcinoma, Metastatic, Intestine Small,                                                                                       
          Jejunum                                      1 (2%)                                                                       
      Hemangiosarcoma                                               1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (48)         (49)         (50)         (50)                                   
      Adenoma                                                                                 1 (2%)                                
      Carcinoma                                                     1 (2%)                                                          
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (2%)                                                                       
      Sarcoma, Metastatic, Mesentery                                             1 (2%)                                             
      Capsule, Adenoma                                                                        1 (2%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - cont                                                                                                             
      Subcapsular, Adenoma                             1 (2%)       1 (2%)       1 (2%)       2 (4%)                                
      Subcapsular, Carcinoma                                        1 (2%)                                                          
   Adrenal Medulla                                    (47)         (49)         (49)         (49)                                   
      Pheochromocytoma Benign                                                    1 (2%)                                             
   Islets, Pancreatic                                 (48)         (49)         (50)         (50)                                   
      Adenoma                                          2 (4%)                                                                       
   Thyroid Gland                                      (48)         (48)         (49)         (49)                                   
      Follicular Cell, Adenoma                         1 (2%)                    1 (2%)                                             
      Follicular Cell, Carcinoma                                                 1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Peritoneum                                         (2)                                                                           
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (50%)                                                                      
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (50%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Epididymis                                         (50)         (50)         (50)         (50)                                   
   Prostate                                           (49)         (49)         (47)         (50)                                   
      Adenoma                                          1 (2%)                                                                       
   Seminal Vesicle                                    (47)         (49)         (49)         (49)                                   
      Adenoma                                                       1 (2%)                                                          
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (2%)                                                                       
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (2%)                                                                       
      Sarcoma, Metastatic, Mesentery                                             1 (2%)                                             
   Testes                                             (50)         (50)         (50)         (50)                                   
      Carcinoma, Metastatic, Intestine Small,                                                                                       
          Jejunum                                      1 (2%)                                                                       
      Hemangioma                                       1 (2%)                                                                       
      Interstitial Cell, Adenoma                       2 (4%)                    2 (4%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (49)         (49)         (50)         (50)                                   
      Mast Cell Tumor Malignant                                                  1 (2%)                                             
   Lymph Node                                         (2)          (1)          (4)          (1)                                    
      Pancreatic, Sarcoma, Metastatic, Lymph Node,                                                                                  
           Mesenteric                                                            1 (25%)                                            
   Lymph Node, Bronchial                              (32)         (36)         (36)         (35)                                   
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (3%)                                                                       
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (3%)                                                                       
   Lymph Node, Mandibular                             (28)         (38)         (30)         (25)                                   
   Lymph Node, Mesenteric                             (48)         (49)         (49)         (50)                                   
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (2%)                                                                       
      Sarcoma, Metastatic, Mesentery                                             1 (2%)                                             
   Lymph Node, Mediastinal                            (39)         (39)         (43)         (36)                                   
      Carcinoma, Metastatic, Intestine Small,                                                                                       
          Jejunum                                      1 (3%)                                                                       
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (3%)                                                                       
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (3%)                                                                       
   Spleen                                             (48)         (48)         (50)         (50)                                   
      Hemangiosarcoma                                  2 (4%)       1 (2%)       1 (2%)                                             
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (2%)                                                                       
   Thymus                                             (40)         (41)         (39)         (40)                                   
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (3%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (49)         (50)         (50)         (50)                                   
      Subcutaneous Tissue, Fibrosarcoma                             1 (2%)                                                          
      Subcutaneous Tissue, Fibrous Histiocytoma                     2 (4%)       2 (4%)                                             
      Subcutaneous Tissue, Hemangioma                                            1 (2%)                                             
      Subcutaneous Tissue, Hemangiosarcoma                                       1 (2%)                                             
      Subcutaneous Tissue, Histiocytic Sarcoma                      1 (2%)                                                          
      Subcutaneous Tissue, Lipoma                      1 (2%)                                                                       
      Subcutaneous Tissue, Sarcoma                                  1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Adenoma                    13 (26%)      7 (14%)                   7 (14%)                               
      Alveolar/Bronchiolar Carcinoma                   6 (12%)      3 (6%)                    4 (8%)                                
      Alveolar/Bronchiolar Carcinoma, Multiple                                   1 (2%)                                             
      Carcinoma, Metastatic, Harderian Gland                                                  1 (2%)                                
      Carcinoma, Metastatic, Intestine Small,                                                                                       
          Jejunum                                      1 (2%)                                                                       
      Hepatoblastoma, Metastatic, Liver                                          1 (2%)                                             
      Hepatocellular Carcinoma, Metastatic, Liver      3 (6%)       2 (4%)       5 (10%)      3 (6%)                                
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (2%)                                                                       
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (2%)                                                                       
      Sarcoma, Metastatic, Mesentery                                             1 (2%)                                             
      Sarcoma, Metastatic, Skin                                     1 (2%)                                                          
      Bronchiole, Adenoma                                           1 (2%)                                                          
   Pleura                                             (1)                       (1)                                                 
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (50)         (50)         (50)         (50)                                   
      Adenoma                                          6 (12%)      4 (8%)       3 (6%)       4 (8%)                                
      Carcinoma                                        1 (2%)       1 (2%)                    2 (4%)                                
      Bilateral, Adenoma                                                         1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  12                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (49)         (50)         (50)                                   
      Carcinoma, Metastatic, Intestine Small,                                                                                       
          Jejunum                                      1 (2%)                                                                       
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (2%)                                                                       
      Plasma Cell Tumor Malignant, Metastatic,                                                                                      
           Uncertain Primary Site                      1 (2%)                                                                       
      Renal Tubule, Adenoma                            1 (2%)                                                                       
      Renal Tubule, Carcinoma                          1 (2%)                                                                       
   Urinary Bladder                                    (48)         (48)         (49)         (50)                                   
      Transitional Epithelium, Papilloma               1 (2%)                                                                       
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)                                   
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Lymphoma Malignant                               3 (6%)       1 (2%)       6 (12%)      3 (6%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  13                                                               
                                                                                                                                   
NTP Experiment-Test: 90004-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                PROPYLENE GLYCOL MONO-T-BUTYL ETHER                            Date: 01/02/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:24:21  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      75 PPM       300 PPM      1200 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            40          38          41          43                                       
     Total Primary Neoplasms                           75          65          70          81                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 30          28          30          39                                       
     Total Benign Neoplasms                            49          39          39          54                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              20          20          26          18                                       
     Total Malignant Neoplasms                         26          26          31          27                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              6           3           7           4                                       
     Total Metastatic Neoplasm                         33           3          17           4                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms               2                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  14                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.